Overview
Following subcutaneous or intramuscular administration, the peptide components would enter systemic circulation and distribute to tissues expressing Kir or K-ATP channels with high density — primarily cardiac muscle, vascular smooth muscle, and the renal tubular epithelium. Renal handling of the compound is unknown, raising concern for accumulation in patients with reduced GFR. Plasma protein binding and volume of distribution have not been characterized.
Proposed mechanism
Based on available descriptions, KLOW is suggested to modulate potassium ion channel activity and cellular electrolyte transport, potentially influencing membrane potential stability in cardiac and skeletal muscle tissue. If it operates via peptide signaling, it may interact with ion channel-regulating receptors to support intracellular potassium homeostasis. The precise molecular targets and downstream signaling cascades have not been characterized in published human studies.
What the evidence supports
Evidence rests primarily on self-reported experience. Controlled studies are lacking.
Graded Anecdotal
Case reports, clinician notes, and user-reported outcomes. Recorded for completeness and labelled plainly so it is never mistaken for data.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
ATP-sensitive potassium channels: structure, function, and therapeutic potential
· Physiol Rev — general mechanistic reference; not specific to KLOW · 2018
- [2]
Inwardly rectifying potassium channels and their physiological functions
· Annu Rev Physiol — general reference · 2016
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.